Japan · Delayed Price · Currency is JPY Renascience Company Description
Renascience Inc. engages in the development and commercialization of pharmaceuticals and medical devices in Japan.
The company is developing RS5614, a PAI-1 inhibitor product candidate for use in the treatment of chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, cutaneous angio-sarcoma, coronavirus lung injury, and interstitial lung disease associated with systemic scleroderma; RS5441, PAI-1 inhibitor for the treatment of alopecia disease that is in Phase I clinical trials; and RS8001, a water-soluble vitamin for use in the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder and menopausal disorder, which is in phase 1 clinical trials.
It is also developing RS9001, a disposable ultrafine endoscope; artificial intelligence based medical solutions; and diagnostic solutions.
The company was incorporated in 2000 and is headquartered in Sendai, Japan.
| Country | Japan |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Toshio Miyata |
Contact Details
Address: 2-1 Seiryo-cho Sendai, 980-8575 Japan | |
| Phone | 81 2 2727 5070 |
| Website | renascience.co.jp |
Stock Details
| Ticker Symbol | 4889 |
| Exchange | Tokyo Stock Exchange |
| Fiscal Year | April - March |
| Reporting Currency | JPY |
| ISIN Number | JP3981100005 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Toshio Miyata | Chief Executive Officer |